未登录.png)
分享.png)
收藏分享 收藏 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Bourhis, J.; Sun, X.; Le Tourneau, C.; Pointreau, Y.; Sire, C.; Kaminsky-Forrett, M-C.; Coutte, A.; Alfonsi, M.; Boisselier, P.; Martin, L.; Delord, J-P.; Clatot, F.; Biau, J.; Rolland, F.; Gollmer, K.; Szyldergemajn, S. A.; Even, C.; Tao, Y. 分享 收藏 Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimensGoffin, J. R.; Nicholas, G.; Mates, M.; Tu, D.; Chen, E.; Laurie, S. A.; Juergens, R.; Robinson, A.; Goss, G.; Reaume, M.; Sun, S.; Christink, K.; Maize, C.; MacFarlan, S.; Sun, X.; Ritter, H.; Seymour, L.; Bradbury, P. A. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
